The bispecific innate cell engager acimtamig (AFM13) was superior to IgG1 monoclonal antibodies in ADCC and in increasing the fraction of cytotoxic NK cells and serial killers...These results demonstrate that CD16A shedding represents an intrinsic feature of NK cell biology that is critical to sustain the antitumoral cytotoxicity of NK cells. This has implications for CD16A engineering of NK cell products and their combination with CD16A-directed NK cell engagers.

P1, N=64, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | N=260 --> 64 | Trial completion date: Mar 2026 --> Sep 2025 | Trial primary completion date: Mar 2026 --> Sep 2025

P1/2, N=45, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | N=30 --> 45 | Trial completion date: Apr 2027 --> Sep 2025 | Trial primary completion date: Apr 2027 --> Sep 2025

In addition, AFM28 is well tolerated and demonstrates pharmacodynamic activity in cynomolgus monkeys. Altogether, our results indicate that AFM28 has the potential to reduce relapse-inducing residual disease and promote long-term remissions for patients with AML and MDS with a favorable safety profile.

P1/2, N=112, Terminated, Affimed GmbH | Trial completion date: Nov 2025 --> Jun 2025 | Recruiting --> Terminated; The trial was prematurely discontinued due to the financial situation of the sponsor and not for safety or efficacy reasons.

P2, N=25, Terminated, Affimed GmbH | N=154 --> 25 | Trial completion date: Nov 2027 --> Jun 2025 | Recruiting --> Terminated | Trial primary completion date: Apr 2026 --> Nov 2024; Due to sponsor decision

P1, N=30, Terminated, Affimed GmbH | Trial completion date: Mar 2026 --> Jun 2025 | Recruiting --> Terminated | Trial primary completion date: Mar 2025 --> Nov 2024; As decided by sponsor

P1/2, N=85, Terminated, Affimed GmbH | Completed --> Terminated; Enrollment into expansion cohorts in Phase 2 part was terminated due to sponsor decision

P1, N=260, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jul 2026 --> Mar 2026 | Trial primary completion date: Jul 2026 --> Mar 2026

P1, N=45, Terminated, Celgene | N=80 --> 45 | Active, not recruiting --> Terminated; Business objectives have changed

P1/2, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Apr 2025 --> Apr 2027

Outcomes of patients with CD30-positive (CD30+) lymphomas have improved with the advent of brentuximab vedotin (BV) and, in Hodgkin lymphoma, anti-PD1 checkpoint inhibitors (CPI)...AFM13-a CD30/CD16A bispecific antibody-activates natural killer (NK) cells to kill CD30+ cells...This therapy showed encouraging preliminary safety and efficacy. ClinicalTrials.gov Identifier: NCT04074746 .